US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review
KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted priority...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: AstraZeneca | Brain | Canada Health | Drugs & Pharmacology | Food and Drug Administration (FDA) | Grants | Merck | Neurofibromatosis | Neurology | New Drug Applications | USA Health